cNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA dDubowitz Neuromuscular Centre ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and ...

Quantum BioPharma Ltd. has announced an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application package for Lucid-21-302 ...

Additionally, if two biopharma companies were given the same molecule in early phase, which would better develop and launch it and why? IDEA also recognized Lilly’s $3.2 billion buyout of ...

Pfizer announced Monday that it will be partnering with Chinese biopharma 3SBIO in a licensing agreement, underscoring continued demand in the pharma industry for Chinese innovation amid trade ...

Shortly after Trump’s election in November, biopharma executives made efforts to court the new administration. The chief executives of Pfizer, Eli Lilly and Company, and the trade organization ...

Former POINT Biopharma CEO Joe McCann joins TAG1 to strengthen Lead-212 supply for TATs. McCann, who previously served as CEO of POINT Biopharma and has led multiple companies through growth, clinical ...

Embracing artificial intelligence (AI) is a compelling option. But, like companies in many other industries, although biopharma leaders and personnel may be psychologically ready to accept AI ...

This week’s Expert View, from Vanessa Almendro of Danaher Corporation, calls for a shift from traditional discovery to a platform-based design model in genomic medicine. She highlights how this ...

As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards? That’s what the European ...

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market. The healthcare ecosystem has undergone a ...